Dovitinib in Neuroendocrine Tumors

NCT01635907 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Advanced Metastatic Paraganglioma
Advanced Metastatic Pheochromocytoma
Recurrent Paraganglioma
Recurrent Pheochromocytoma
Unresectable Paraganglioma
Unresectable Pheochromocytoma

Interventions

DRUG: Dovitinib

Sponsor

Abramson Cancer Center at Penn Medicine